JPS61254861A - Modified human gamma-globulin - Google Patents

Modified human gamma-globulin

Info

Publication number
JPS61254861A
JPS61254861A JP9609885A JP9609885A JPS61254861A JP S61254861 A JPS61254861 A JP S61254861A JP 9609885 A JP9609885 A JP 9609885A JP 9609885 A JP9609885 A JP 9609885A JP S61254861 A JPS61254861 A JP S61254861A
Authority
JP
Japan
Prior art keywords
globulin
human
reagent
measured
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9609885A
Other languages
Japanese (ja)
Inventor
Taku Nakatate
中楯 卓
Akishige Hamano
浜野 明栄
Hideaki Shibata
英昭 柴田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NITSUSUI SEIYAKU KK
Nissui Pharmacetuical Co Ltd
Original Assignee
NITSUSUI SEIYAKU KK
Nissui Pharmacetuical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NITSUSUI SEIYAKU KK, Nissui Pharmacetuical Co Ltd filed Critical NITSUSUI SEIYAKU KK
Priority to JP9609885A priority Critical patent/JPS61254861A/en
Priority to DE19863615384 priority patent/DE3615384A1/en
Publication of JPS61254861A publication Critical patent/JPS61254861A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To make possible automatic biochemical analysis by adjusting monomer type IgG and polymer type IgG to one to 0.7 or above as modified human gamma-globulin and using the same as an antigen in measuring the RF in the human serum. CONSTITUTION:The human gamma-globulin is dissolved to 1% concn. in 0.02M HEPES buffer soln. (7.2phipH) contg. NaN3 at 0.1% concn. and NaCl at 0.8% concn. and the soln. is treated for 30min at 53-63 deg.C, by which the soln. is thermally modified. The light absorptivity of water blank is first measured by using an automatic biochemical analyzing instrument, then the absorptivity of the specimen serum S and the 1st reagent R1 consisting of NaCl, NaN3, chondoloitin sulfuric acid, TX-100 and polyethylene glycol is measured for 5min; further the 2nd reagent R2 consisting of the modified human gamma-globulin subjected to the above-mentioned thermal modification is added to the soln. and the absorptivity thereof is measured.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明はr−グロブリン変性物に係シ、殊にヒトγ−グ
ロブリン変性物に係る。
DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to modified r-globulin, particularly to modified human γ-globulin.

r−グロブリンは生体産生蛋白の1種であり、各種免疫
反応に使用されている。本発明によるヒトr−グロブリ
ン変性物はこの免疫反応において反応性を向上させるた
めに利用することができる。
R-globulin is a type of biologically produced protein and is used in various immune reactions. The modified human r-globulin according to the present invention can be used to improve reactivity in this immune reaction.

(従来の技術) 免疫複合体病、例えば慢性関節リウマチに膿病した患者
の血清中にはRP即ちリウマトイド7アクタ(Rheu
matoid Factor、リウマチ因子)が見られ
、これは主として分子量約100万のマクログロブリン
から構成されており、沈降定数198のIgMではない
かと推定される物質であυ自己、同種又は異種のr−グ
ロブリンに対して抗体として作用する。
(Prior Art) RP, or rheumatoid 7 acta (Rheu
matoid factor (rheumatoid factor), which is mainly composed of macroglobulin with a molecular weight of approximately 1 million, is a substance presumed to be IgM with a sedimentation constant of 198. acts as an antibody against

従って、ヒトγ−グロブリンを抗原としRPを抗体とし
て免疫反応させ、これによってリウマチ、殊に慢性関節
リウマチの診断を行なうことは既に実用化されるに至っ
ている。このためのRF測定法としては、ポリスチレン
ラテックス粒子又はベントナイト粒子を用い凝集反応を
利用するRAテストと、羊赤血球を用い凝集反応を利用
するWallar−Rose反応1及びこのWalla
r−Rose反応における手段を簡略化させ九Roll
er変法及びRAHAテストがあシ、現在は主として上
記RAテストとRAHAテストとが汎用されている。こ
れら測定法においては抗原として何れも未変性のヒトr
−グロブリンを用いておシ、RAテストは鋭敏度が高い
が非特異的反応による陽性率も高い点に問題点があシ、
一方RAHAテストは特異性が高いが鋭敏度蛛難があシ
且つ反応所要時間が比較的長い点に問題点がある。
Therefore, it has already been put into practical use to diagnose rheumatism, especially rheumatoid arthritis, by causing an immune reaction using human γ-globulin as an antigen and RP as an antibody. RF measurement methods for this purpose include the RA test that uses polystyrene latex particles or bentonite particles and uses an agglutination reaction, and the Wallar-Rose reaction 1 that uses sheep red blood cells and uses an agglutination reaction.
Nine Rolls by simplifying the means in the r-Rose reaction
Although the er modified method and the RAHA test are used, the RA test and the RAHA test are currently mainly used. In these measurement methods, native human r
- Although the RA test using globulin has high sensitivity, the problem is that the positive rate due to non-specific reactions is also high.
On the other hand, the RAHA test has high specificity, but has problems in that it has poor sensitivity and requires a relatively long reaction time.

(発明が解決しようとする問題点並びに問題点を解決す
るための手段及び作用) 従って、本発明者等は抗原と抗体とが特異的に反応し、
鋭敏度が高く、シかも反応所要時間が短かいRF測定法
を開発する九めに鋭意研究を重ね九処、ヒトγ−グロブ
リン変性物を抗原として用いることによシ反応に特異性
をもたらし得ること並びに′PiT要時間を短縮させ得
ることを見出し、本発明を完成するに至った。
(Problems to be Solved by the Invention and Means and Effects for Solving the Problems) Therefore, the present inventors have discovered that antigens and antibodies specifically react,
After conducting extensive research to develop an RF measurement method with high sensitivity and short reaction time, we found that using denatured human γ-globulin as an antigen could bring specificity to the reaction. In addition, the present inventors have discovered that the time required for 'PiT can be shortened, and have completed the present invention.

本発明によるヒトγ−グロブリン変性物は、モノマー性
IgGとポリマー性1gGとが1対帆7又はそれ以上で
あることを特徴としている。
The modified human γ-globulin according to the present invention is characterized in that the ratio of monomeric IgG to polymeric IgG is 1 to 7 or more.

本発明によるヒトγ−グロブリン変性物を得る念めの変
性法としては、自体周知の熱変成法、尿素変性法等の任
意の方法を利用することができる。
As a preliminary modification method for obtaining the human γ-globulin modified product according to the present invention, any known method such as a thermal denaturation method or a urea denaturation method can be used.

本発明によるヒトγ−グロブリン変性物においてモノマ
ー性IgGとポリマー性IgGとが1対0.7又はそれ
以上と規定されているのはポリマー性IgGの含有量が
これ以下では反応性向上に寄与する度合が低いからであ
シ、ポリマー性IgG含量に上限はなく、例えばポリマ
ー性IgG 100 %のものを舌 分離して使用することができる。
The reason why the ratio of monomeric IgG to polymeric IgG in the human γ-globulin modified product according to the present invention is defined as 1:0.7 or more is that if the content of polymeric IgG is less than this, it will contribute to improving the reactivity. Since the content is low, there is no upper limit to the content of polymeric IgG, and for example, 100% polymeric IgG can be used after being separated.

尚、本発明によるγ−グロブリン変性物を抗原として用
いRF測測定行なう場合には、このヒトγ−グロブリン
変性物の他に水溶性高分子物質を反応促進剤として含有
する緩衝液が検体血清に添加されて抗原抗体反応が行わ
れる。この場合の水溶性高分子物質としてはポリエチレ
ングリコール、多糖類又は蛋白質を用いることができ、
この場合の多糖類や蛋白質としてはデキストラン、コン
ドロイチン硫酸、アルギン酸、アラビアガム、メチプ ルセルロース、ヘパリン、ゲラチン、アルズミン、カゼ
イン、フィブリノーゲン、レクチン、ConA。
When performing RF measurement using the denatured human γ-globulin according to the present invention as an antigen, a buffer containing a water-soluble polymeric substance as a reaction accelerator in addition to the denatured human γ-globulin is added to the sample serum. is added, and an antigen-antibody reaction is performed. In this case, polyethylene glycol, polysaccharide or protein can be used as the water-soluble polymer substance,
In this case, the polysaccharides and proteins include dextran, chondroitin sulfate, alginic acid, gum arabic, methylcellulose, heparin, gelatin, alsmin, casein, fibrinogen, lectin, and ConA.

P)IA等を例示することができる。P) IA etc. can be exemplified.

本発明によるヒトγ−グロブリン変性物を用いてRF測
測定実施する場合には反応に特異性があシ、上記反応促
進剤の使用とも関連して反応性が高いので、従来の凝集
反応に代えて沈降反応を利用でき、その結果生化学分析
装置を利用して濁度に基(RFの測定や判定を行なうこ
とが可能となシ、従来の肉眼観察判定による誤差の導入
を排除することができる。
When carrying out RF measurement using the human γ-globulin modified product according to the present invention, the reaction is not specific and the reactivity is high due to the use of the reaction accelerator, so it is recommended to use it instead of the conventional agglutination reaction. As a result, it is possible to measure and judge RF based on turbidity using a biochemical analyzer, eliminating the introduction of errors caused by conventional visual observation judgments. can.

中ブ・ (本発明によるヒトγ−グロブリン変I物の利用可能性
) ・1°f 本発明によるヒトr−グロブリン変!物は免疫比濁法に
よる上記RF測定以外に各種の免疫複合体病の診断用試
薬として用いられ、その免疫反応性の向上をもたらすこ
とが期待される。
(Usability of human γ-globulin variant I according to the present invention) -1°f Human r-globulin variant according to the present invention! The product can be used as a diagnostic reagent for various immune complex diseases in addition to the above-mentioned RF measurement using immunoturbidimetry, and is expected to improve immunoreactivity.

更に、細胞レセプタに対する免疫複合体の結合及び抑制
に際して免疫複合体の検出を行なう際にIgGがアイソ
トープ等でラベルして用いられているが、このIgGと
して本発明による変性物を用いることも期待される。
Furthermore, IgG is used after being labeled with an isotope, etc. when detecting immune complexes during binding and inhibition of immune complexes to cell receptors, and it is also expected that modified products according to the present invention may be used as this IgG. Ru.

(製造例等) ・1°f 次に本発明によるヒトr−グロブリン変を物の製造例及
びこの変性物をRF測測定用いた応用例について本発明
を説明する。
(Production Examples, etc.) - 1°f Next, the present invention will be explained with reference to production examples of the modified human r-globulin according to the present invention and application examples of using the modified products using RF measurement.

製造例1 (ヒトr−グロブリンの熱変性と、この変性グロブリン
をRF測測定用いた場合のRFとの反応性) NaN5を0.11及びNaCtを0.8 %濃度で含
有する0、02MのHEPES緩衝液(pH7,2)に
ヒトγ−グロブリン(シグマ社製の「cohnフラクシ
ョン■」)を1チ濃度となるように溶解させ、53〜6
3℃の種々温度(2℃間隔)で30分間処理して熱変性
を行なった。
Production Example 1 (Thermal denaturation of human r-globulin and reactivity with RF when this denatured globulin is used for RF measurement) Human γ-globulin (“Cohn Fraction ■” manufactured by Sigma) was dissolved in HEPES buffer (pH 7.2) to a concentration of 1%.
Heat denaturation was performed by treating at various temperatures of 3°C (2°C intervals) for 30 minutes.

これを0.1 M燐酸緩衝液で平衡化させたセファデッ
クスG−200(ファルマシア社製)にょシゲル濾過し
てポリマー性IgGとモノマーi1gGとに分離し、そ
れぞれの蛋白濃度をローリ−法に従って測定して両者の
比率を求めた結果は下記表1に示される通シであった。
This was filtered through gel using Sephadex G-200 (manufactured by Pharmacia) equilibrated with 0.1 M phosphate buffer to separate polymeric IgG and monomer i1gG, and the protein concentration of each was measured according to the Lowry method. The results of calculating the ratio between the two were as shown in Table 1 below.

表  1 次に、これらの各変性ヒトγ−グロブリンを用い、後記
便用例に記載の方法に従い免疫比濁法に適用して反応性
を濁度測定により調ぺた結果は第1図のグラフに示され
る通シであった。このグラフから、変性温度が59〜6
1℃の間である場合に反応性に影響を及ぼす急激な変更
点があシ、変性温度を61℃以上に設定する場合には反
応性に及ぼす影響が緩やかとなることが判る。この結果
と、上記表1に示される結果とを考慮すればモノマー性
IgGに対するポリi−性1gGの比が1対0.7又は
それ以上の場合に有利であることが判る0尚、各処理温
度(53−63℃、2℃間階)で変性させたヒトr−グ
ロブリンの分画からモノマー性IgG 100チ部分及
びポリマー性IgG 100チ部分を採取し、これらを
用いてO/1o12/1o14/10.6/10%8/
10及び10/1oの6段階の希釈系列を作成し、これ
らを用い且つ前述のように0・D・値を測定して反応性
に関する影響t−調べた結果は第2図のグラフに示され
る通シであった。このグラフから%/−F−性1gG1
00*(1’性度0)のヒトγ−グロブリンは測定に供
し得ないこと、変性度が高くなるにつれて反応性に好影
響が現われるが熱変性の場合には変性湿度を61℃に設
定した場合が最も良好であることが判る。
Table 1 Next, each of these modified human γ-globulins was applied to immunoturbidimetry according to the method described in the convenience example below, and the reactivity was investigated by turbidity measurement. The results are shown in the graph of Figure 1. It was a common knowledge. From this graph, the denaturation temperature is 59-6
It can be seen that when the denaturation temperature is between 1°C, there is a sudden change that affects the reactivity, but when the denaturation temperature is set at 61°C or higher, the effect on the reactivity becomes gradual. Considering this result and the results shown in Table 1 above, it can be seen that it is advantageous when the ratio of poly-i-1gG to monomeric IgG is 1:0.7 or more. 100 parts of monomeric IgG and 100 parts of polymeric IgG were collected from the fraction of human r-globulin denatured at temperature (53-63 degrees Celsius, 2 degrees Celsius), and these were used to extract O/1o12/1o14. /10.6/10%8/
A 6-step dilution series of 10 and 10/1o was created, and using these, the 0.D. It was common sense. From this graph, %/-F-sexuality 1gG1
00* (1' degree of 0) human γ-globulin cannot be used for measurement, and as the degree of denaturation increases, a favorable effect appears on reactivity, but in the case of heat denaturation, the denaturation humidity was set at 61 °C. It turns out that the case is the best.

製造例2 (ヒトγ−グロブリンの尿素変性と、この変性グロブリ
ンt−RF測定に用いた場合のRFとの反応性) 6Mの尿素と0.15 M のNaC2を含有する溶液
にヒトr−グロブリン(シグマ社製の「Cohnフラク
ション■」を1%濃度となるように溶解させ、これを6
M尿素に対して室温で24時間透析し、更に0.15 
M NaC2に対して4℃で72時間透析し、次いで更
に0.1%のNaN3と0.8%のNaCLを含有する
0、02 M HEPES緩衝液(p)17.2)に対
して4℃で24時間透析し、その後は製造例1における
と同様にしてゲル濾過処理によシボリマー性IgGとモ
ノマー性IgGとに分離し、蛋白濃度の比率を求めた処
、1.26対1でおった。
Production Example 2 (Urea denaturation of human γ-globulin and reactivity with RF when used for t-RF measurement of this denatured globulin) Human r-globulin was added to a solution containing 6 M urea and 0.15 M NaC2. (Dissolve Sigma's "Cohn Fraction ■" to a concentration of 1%, and add 6
Dialyzed against M urea for 24 hours at room temperature and further diluted with 0.15
Dialyzed for 72 h at 4 °C against M NaC2 and then further dialyzed at 4 °C against 0.02 M HEPES buffer (p) 17.2) containing 0.1% NaN3 and 0.8% NaCL). The protein was dialyzed for 24 hours, and then separated into cibolimeric IgG and monomeric IgG by gel filtration in the same manner as in Production Example 1.The protein concentration ratio was determined to be 1.26:1. .

尚、上記のポリマー性IgG対モノマー性1gGとが1
.26対1であるヒトr−グロブリン変性物、本変性法
で分離されたモノマー性IgG 100 %の非変性物
及びポリマー性IgG 100 %の完全変性物をそれ
ぞれ用いて希釈系列O/10 % 2/10 % ’/
10 s6/10 % 8/10及び10/1oの6段
階を作成し後記参考例に記載の如(0,D、値を測定し
、反応性に及ぼす影響を調べた結果は第3図のグラフに
示される通υであった。このグラフからポリマー性Ig
G含量の高い、即ち変性度の高いと)r−グロブリンを
使用する方が有利であυ、未変性物を用いる場合には測
定不可能となることが判る。
Note that the above polymeric IgG versus monomeric 1gG is 1
.. A dilution series of O/10% 2/26 to 1 human r-globulin denatured product, 100% undenatured monomeric IgG and 100% completely denatured polymeric IgG separated by this modification method were used. 10%'/
10s6/10% 6 stages of 8/10 and 10/1o were created and the values were measured as described in the reference example below (0, D, and the results of investigating the effect on reactivity are shown in the graph in Figure 3. From this graph, the polymeric Ig
It can be seen that it is more advantageous to use r-globulin (with a high G content, ie, a high degree of modification), and that it becomes impossible to measure when unmodified material is used.

使用例 (本発明によるヒトr−グロブリン変性物を用いたRF
測測定 に)使用機器及びパラメータ設定 このRF測測定は省力化轡のために日立705型生化学
自動分析装置が用いられた。この分析装れた。
Example of use (RF using modified human r-globulin according to the present invention)
(For measurement) Equipment used and parameter settings For this RF measurement, a Hitachi model 705 biochemical automatic analyzer was used to save labor. This analysis was done.

表  2 (B)試薬 a)第1試薬(R1) 0.1 M  NaC2と、0.1 To NaN3と
、0.1%コンドロイチン硫酸と、0.1 To TX
−100(界面活性剤)と、0.25%ポリエチレング
リコール(分子量4000)とを含有する0、02M 
HEPI8緩衝液(pE 7.2) b)第2試薬(R2) 0.1 M (0,8% ) NaCAと、0.15b
 NaN3と、1.0 %ヒトr−グロブリン(シグマ
社製の「Cohn Fracton If J ) t
−含有する0、02M HEPES緩衝液を61℃で3
0分間熱変性させたもの(クロプリンのモノマー性1g
G対ポリマー性IgG比が1対0.71のもの) (C)  操作方法 測定操作の概略は第4図に示されている通夛であシ、先
ず水ブランクの吸光度が測定され、次いで検体血清S及
び第1試薬R1が又はこれらが同時に添加されて吸光度
が10分間に亘シ連続的に即ち20秒間隔で31回測定
される。この測定期間内に、即ち第1試薬R1の添加か
ら5分後に第2試薬R2が添加される。即ち、第1試薬
R1の添加から5分間以内の吸光度測定は検体血清Sと
第1試薬R1との反応液についてなされ、−力筒1試薬
R1の添加から5分間経過以降の吸光度測定は検体血清
Sと第2試薬R2との反応液についてなされる訳である
。尚、第1試薬R1の添加後に31回に亘シ測定された
各吸光度値については分析装置に内蔵され九演算機構に
よシ水ブランクの吸光度値が自動的に差引かれる。
Table 2 (B) Reagent a) First reagent (R1) 0.1 M NaC2, 0.1 To NaN3, 0.1% chondroitin sulfate, 0.1 To TX
-100 (surfactant) and 0.02M containing 0.25% polyethylene glycol (molecular weight 4000)
HEPI8 buffer (pE 7.2) b) Second reagent (R2) 0.1 M (0.8%) NaCA and 0.15b
NaN3 and 1.0% human r-globulin (“Cohn Fracton If J” manufactured by Sigma)
- containing 0.02 M HEPES buffer at 61 °C for 3
Heat denatured for 0 minutes (1 g of monomeric clopurin)
G to polymeric IgG ratio of 1 to 0.71) (C) Operation method The measurement procedure is generally as shown in Figure 4. First, the absorbance of a water blank is measured, and then the absorbance of the sample is measured. Serum S and first reagent R1 or both are added and the absorbance is measured continuously over a period of 10 minutes, 31 times at 20 second intervals. Within this measurement period, ie 5 minutes after the addition of the first reagent R1, the second reagent R2 is added. That is, the absorbance measurement within 5 minutes from the addition of the first reagent R1 is performed on the reaction solution of the sample serum S and the first reagent R1, and the absorbance measurement after 5 minutes from the addition of the first reagent R1 is performed on the sample serum S. This is done for the reaction solution of S and the second reagent R2. It should be noted that for each absorbance value measured 31 times after the addition of the first reagent R1, the absorbance value of the water blank is automatically subtracted by nine calculation mechanisms built into the analyzer.

本使用例の場合には、水ブランクの測定後に、前記に)
項におけるパラメータ設定値から明らかなように検体血
清但)20μtと第1試薬であるブランク液(R1) 
350μtが添加されて実質的測定が開始されその5分
後に第2試薬である変性ヒトγ−グロブリン溶液(R2
)50μtが添加され、更に5分間に亘ル測定が行われ
た。尚、前記(6)項の機器パラメータにおけるAS8
AY C0DEの項において設定値がENDとなされて
いるように、ブランク即ち(8+R1)の測定に関して
はその最後2回(第14回目と第15回目)に測定され
た吸光度値の平均値が、又反応液(R2が更に添加され
てSと反応した液)の測定に関してもその最後2回(第
30回目と第31回目)に測定された吸光度の平均値が
採用されている。
In this case, after measuring the water blank)
As is clear from the parameter setting values in Section 1, the sample serum (However) 20 μt and the blank solution (R1) which is the first reagent.
350 μt was added to start the actual measurement, and 5 minutes later, the second reagent, denatured human γ-globulin solution (R2
) 50 μt was added, and the measurement was continued for an additional 5 minutes. In addition, AS8 in the equipment parameters in item (6) above
As the setting value is set to END in the AY C0DE section, the average value of the absorbance values measured in the last two measurements (14th and 15th measurements) is also Regarding the measurement of the reaction solution (the solution in which R2 was further added and reacted with S), the average value of the absorbance measured in the last two measurements (the 30th and 31st measurements) was used.

(ロ)検量線 2′mの標準血清、即ちRAHAテストによシ陰性と判
定された血清と、1280倍と判定された血清とを用い
て次の希釈系列を作成した。
(b) The following dilution series was prepared using the standard serum with a standard curve of 2'm, that is, the serum determined to be negative by the RAHA test, and the serum determined to be 1280 times higher.

0   (無希釈の陰性血清) 128   (1:9) 256   (2:8) 384   (3ニア) 512   (4:6) 640   (5:5) 768   (6:4) 896   (7:3) 1024   (8:2) 1152   (9:1) 1280   (無希釈の陽性血清) 次に、上記0項の操作方法に従って、これらの血清液を
検体血清(S)とし各20μtと、第1試薬(R1)3
50μtと、第2試薬(R2) 50μtとを用いて吸
光度測定を行ない、吸光度(mABs )とRF値(希
釈倍数に相当)との関係をプロットした処、第5図に示
される過多のグラフが得られた。このグラフから明らか
な通夛、吸光度値とRF値とは安定な直線関係を有して
おシ、従ってこのグラフを標準検量線として用いること
ができるので、このグラフにおける吸光度値とRF値と
の関係を自動分析装置の記憶機構に検量線として記憶さ
せる。
0 (undiluted negative serum) 128 (1:9) 256 (2:8) 384 (3 near) 512 (4:6) 640 (5:5) 768 (6:4) 896 (7:3) 1024 (8:2) 1152 (9:1) 1280 (undiluted positive serum) Next, according to the procedure in section 0 above, these serum solutions were used as sample serum (S), 20 μt each, and the first reagent (R1 )3
When absorbance was measured using 50μt and 50μt of the second reagent (R2) and the relationship between absorbance (mABs) and RF value (corresponding to the dilution factor) was plotted, the excessive graph shown in Figure 5 was obtained. Obtained. As is clear from this graph, there is a stable linear relationship between the absorbance value and the RF value, and therefore this graph can be used as a standard calibration curve. The relationship is stored as a calibration curve in the storage mechanism of the automatic analyzer.

(ト)従来法との相関 RF値が未確定な血清(70検体)について上記り項に
記載の方法に従って吸光度測定を行ない0、D、値を求
め、一方これらの各検体血清につき従来のラテックス凝
集法を適用し検体血清を倍々希釈して伺倍迄凝集するか
の凝集限界濃度を調べて、これら両方法の相関関係をプ
ロットした処、第6図に示される通夛のグラフが得られ
た。このグラフから明らかな通シ両方法は良好な相関を
有しておシ、従ってこの測定法は充分な実用性を有して
いることが判る。
(G) Correlation with conventional method Absorbance was measured for serum (70 samples) for which the RF value was undetermined according to the method described in the above section, and the 0, D, and D values were determined. Applying the agglutination method, we diluted the sample serum several times to find out the agglutination limit concentration that would cause it to agglutinate to the same extent as expected, and plotted the correlation between these two methods, and the general graph shown in Figure 6 was obtained. Ta. It is clear from this graph that the two methods have a good correlation, and therefore this measuring method has sufficient practicality.

(発明の効果) 本発明によるヒトγ−−グロブリン変性物は免疫反応に
用いる場合にその特異的反応性を向上させることができ
、殊にヒト血清中のRF測測定際してこれを抗原として
用いる時にその測定を生化学的自動分析機器で行なうこ
とを可能ならしめる。
(Effects of the Invention) The human γ-globulin modified product according to the present invention can improve the specific reactivity when used for immune reactions, and in particular, it can be used as an antigen during RF measurement in human serum. When used, it is possible to perform the measurement with an automatic biochemical analysis device.

尚、変性それ自体は生化学分野において公知の手法によ
シ比較的簡便に行なうことができる。
Incidentally, the denaturation itself can be carried out relatively easily by a method known in the field of biochemistry.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は熱変性させた本発明によるヒトγ−グロブリン
変性物をRFと反応させた場合の、変性温度と濁度との
関係を示すグラフ、第2図は各種温度条件で変性された
本発明によるヒトr−グロブリン変性物の希釈率がRF
との反応性に及ぼす影響を示すグラフ、第3図は尿素変
性させた本発明によるヒトr−グロブリン変性物に関す
るものであって第2図と同様のグラフ、第4図は本発明
によるヒトγ−グロブリン変性物を用いてRF測測定行
なう場合の操作を例示する説明図、第5図は第4図のR
F測測定おける標準検量線を示すグラフ、第6図は第4
図に略示されたRF測定法と従来法であるラテックス凝
集法との相関関係を示すグラフである。 特許出願人  日水製薬株式会社 第1図 突栓X序(”C) 第4図 第5図 RF値(h党倍率) 第6図 従来のフチ0.クス5廷黍清 (RA〒ズト)(恭状侶
牢) 手続補正書 昭和60年7月5日 特許庁長官 宇 賀  道 部 殿 1、事件の表示 昭和60年特許願第96098号 2、発明の名称 ヒトツーグロブリン変性物 3、補正をする者 代表者 小林泰明 4、代理人〒105 明細書の発明の詳細な説明の欄 (1)明細書第1頁第17行に「罹病」とあるを「罹病
」と補正する。 (2)同第1頁第19行に「リウマチ」とあるを「リウ
マトイド」と補正する。 (3)同第2頁第11及び12行に「υallar J
とあるを Ii′υaaler 」と補正する。 (4)同第8頁第2行に「間階」とあるをr間隔」と補
正する。 (5)同第12頁第11行にr Fracton Jと
あるを(rFraction jと補正する。
Figure 1 is a graph showing the relationship between denaturation temperature and turbidity when heat-denatured human γ-globulin according to the present invention is reacted with RF. The dilution rate of the modified human r-globulin according to the invention is RF
FIG. 3 is a graph showing the effect on the reactivity of human r-globulin according to the present invention which has been denatured with urea, and is similar to FIG. 2. FIG. - An explanatory diagram illustrating the operation when performing RF measurement using modified globulin, Figure 5 is R of Figure 4.
A graph showing the standard calibration curve for F measurement, Figure 6 is
2 is a graph showing the correlation between the RF measurement method shown schematically in the figure and the conventional latex aggregation method. Patent Applicant: Nissui Pharmaceutical Co., Ltd. Figure 1: Jacket (Declaration of Honor) Procedural Amendment July 5, 1985 Michibe Uga, Director General of the Patent Office1, Indication of the Case Patent Application No. 96098 of 19852, Name of Invention Human Two Globulin Modified Product3, Amendment Representative: Yasuaki Kobayashi 4, Agent: 105 Detailed explanation of the invention in the specification (1) In the 1st page, line 17 of the specification, the word "affected by disease" is amended to read "affected by disease." (2) On page 1, line 19, the word "rheumatoid" is corrected to "rheumatoid." (3) On page 2, lines 11 and 12, “υallar J
Correct the statement as "Ii′υaaler." (4) In the second line of page 8, the words ``interstairs'' are corrected to read ``r spacing''. (5) In the 11th line of page 12, the text "rFracton J" is corrected to (rFraction j).

Claims (1)

【特許請求の範囲】[Claims] (1)モノマー性IgGとポリマー性IgGとが1対0
.7又はそれ以上であることを特徴とする、ヒトγ−グ
ロブリン変性物。
(1) Monomeric IgG and polymeric IgG are 1:0
.. 7 or more.
JP9609885A 1985-05-08 1985-05-08 Modified human gamma-globulin Pending JPS61254861A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP9609885A JPS61254861A (en) 1985-05-08 1985-05-08 Modified human gamma-globulin
DE19863615384 DE3615384A1 (en) 1985-05-08 1986-05-07 Method for determining rheumatoid factor and denatured, human gamma -globulin for the method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9609885A JPS61254861A (en) 1985-05-08 1985-05-08 Modified human gamma-globulin

Publications (1)

Publication Number Publication Date
JPS61254861A true JPS61254861A (en) 1986-11-12

Family

ID=14155915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9609885A Pending JPS61254861A (en) 1985-05-08 1985-05-08 Modified human gamma-globulin

Country Status (1)

Country Link
JP (1) JPS61254861A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01213573A (en) * 1988-02-22 1989-08-28 Wako Pure Chem Ind Ltd Method for measuring c reactive protein
JPH04299263A (en) * 1991-03-28 1992-10-22 Meiji Seika Kaisha Ltd Stabilizing method for rheumatoid factor measuring reagent
JP2009534630A (en) * 2006-03-30 2009-09-24 ギロス パテント アーべー IG assay
CN105181962A (en) * 2015-09-02 2015-12-23 郁东 Rheumatoid factor detection reagent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512419A (en) * 1978-07-13 1980-01-29 Teikoku Hormone Mfg Co Ltd Immunological measurement and reagent therefor
JPS5610254A (en) * 1979-07-07 1981-02-02 Wako Pure Chem Ind Ltd New rheumatism factor measuring reagent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512419A (en) * 1978-07-13 1980-01-29 Teikoku Hormone Mfg Co Ltd Immunological measurement and reagent therefor
JPS5610254A (en) * 1979-07-07 1981-02-02 Wako Pure Chem Ind Ltd New rheumatism factor measuring reagent

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01213573A (en) * 1988-02-22 1989-08-28 Wako Pure Chem Ind Ltd Method for measuring c reactive protein
JPH04299263A (en) * 1991-03-28 1992-10-22 Meiji Seika Kaisha Ltd Stabilizing method for rheumatoid factor measuring reagent
JP2009534630A (en) * 2006-03-30 2009-09-24 ギロス パテント アーべー IG assay
CN105181962A (en) * 2015-09-02 2015-12-23 郁东 Rheumatoid factor detection reagent
CN105181962B (en) * 2015-09-02 2016-09-14 郁东 A kind of rheumatoid factor detection reagent

Similar Documents

Publication Publication Date Title
CN102759631B (en) The latex enhancing immune of a kind of quantitative detection Procalcitonin PCT is than turbid kit
Boyden et al. Precipitin testing with special reference to the photoelectric measurement of turbidity
JP3331251B2 (en) Method for measuring hemoglobin adducts
JPS6367864B2 (en)
Maiolini et al. A sandwich method of enzyme-immunoassay. II. Quantification of rheumatoid factor
CH649306A5 (en) CARRIER-TIED IMMUNGLOBULIN CLEAVAGE PRODUCT AND ITS USE FOR IMMUNOLOGICAL ANALYZING METHODS.
CN108570104A (en) Recombinating adiponectin antigen, antibody and adiponectin nano rubber latex enhances immunoturbidimetry kit
JPS60192263A (en) Standard material for measuring immunocomplex and masuring method of immunocomplex using said material
JPS61254861A (en) Modified human gamma-globulin
JPS6345066B2 (en)
JPS63315953A (en) Method for measuring content of trace material in blood or bodily fluid
EP0043608A1 (en) Hemolytic method for the kinetic determination of antistreptolysin O antibodies in blood or serum samples, using oxidised SO
JP3277336B2 (en) Reagent for measuring rheumatoid factor, method for measuring rheumatoid factor, and method for producing antigen for measuring rheumatoid factor
JPS63196855A (en) Specific immunoassay
Hansson et al. A simple routine method for detecting hidden rheumatoid factors
Hibrawi et al. Improved estimation of urinary myoglobulin by counterimmunoelectrophoresis, as compared with the double immunodiffusion technique
JPH08193999A (en) Immune measuring method
JPS59136657A (en) Reagent for measuring eighth factor of blood clotting
DK149909B (en) IMMUNOENZYMATIC PROCEDURE FOR THE DETECTION AND DETERMINATION OF TRIIODTHYRONIN OR TRIIODTHYRONIN ANTIBODY AND CONNECTING PRODUCTS FOR THE EXECUTIVE PROCEDURE
JP3423085B2 (en) Immunoassay
US4501816A (en) Method of determining immunoglobulin levels in mammals
JPS61254860A (en) Measuring method for rf
JPS58182558A (en) Method of measuring antigen
JPS587560A (en) Reagent for measuring copper, zinc-super oxidedismutase
JPS6262291B2 (en)